Korea / KHIDI President Talks Domestic Vaccine R&D
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Korea Health Industry Development Institute (KHIDI) is a government-affiliated institution which performs professional and systematic support to develop domestic health industry and enhance health services.
Since its establishment in 1999, KHIDI has led expansion of healthcare R&D investment and building competitiveness of Korea’s healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. We are also witnessing rapid growth of global healthcare sector – especially in attracting foreign patients and exporting healthcare service providers along with healthcare systems. This is a valuable outcome we have earned through years of efforts on global advancement and outreach in this sector.Since its establishment in 1999, KHIDI has been playing a major role in the industry development as the nation’s only one organization responsible for fostering health industry. While we have striven to produce more successful research outcomes by means of greater investments in Health Technology (HT) R&D, KHIDI also took the initiative in increasing competitiveness in different areas of health industry, including pharmaceuticals, medical devices, foods, and beauty & cosmetics businesses.
Contact details:
Address: 187 Osongsaengmyeong2(i)-ro, Gangoe-myeon, Cheongwon-gun, Chungcheongbuk-do, 363-951 Korea
Tel: +82-43-713-8000 ~ 8005
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion…
See our Cookie Privacy Policy Here